“The spin-off of Mallinckrodt Prescription drugs to change into an impartial firm marks a major new chapter in Mallinckrodt’s proud historical past,” stated Mark Trudeau, President and CEO of Mallinckrodt. “We’re nicely positioned to leverage the abilities and capabilities which were developed over 145 years of prescription drugs business expertise. There are numerous advantages to our being impartial that may accrue to Mallinckrodt’s shareholders, prospects and staff going ahead. We’re excited concerning the development alternatives that lie forward.”
Study extra at www.mallinckrodt.com.